As of close of business last night, Poseida Therapeutics Inc’s stock clocked out at $2.79, down -7.31% from its previous closing price of $3.01. On the day, 518020 shares were traded. PSTX stock price reached its highest trading level at $2.9300 during the session, while it also had its lowest trading level at $2.7650.
Ratios:
To gain a deeper understanding of PSTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 3.18. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 04, 2023, initiated with a Buy rating and assigned the stock a target price of $15.
On January 07, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $24.
On May 18, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $40.BTIG Research initiated its Buy rating on May 18, 2021, with a $40 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTX now has a Market Capitalization of 289.95M and an Enterprise Value of 163.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.16 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 2.52 whereas that against EBITDA is -1.50.
Stock Price History:
Over the past 52 weeks, PSTX has reached a high of $4.27, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 3.3686, while the 200-Day Moving Average is calculated to be 2.6512.
Shares Statistics:
It appears that PSTX traded 744.02K shares on average per day over the past three months and 511.43k shares per day over the past ten days. A total of 95.64M shares are outstanding, with a floating share count of 61.48M. Insiders hold about 36.28% of the company’s shares, while institutions hold 47.08% stake in the company. Shares short for PSTX as of Mar 15, 2024 were 3.84M with a Short Ratio of 5.54, compared to 3.67M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.97% and a Short% of Float of 5.36%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$0.48, while EPS last year was -$0.45. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.36 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.26 and -$2.06 for the fiscal current year, implying an average EPS of -$1.67. EPS for the following year is -$1.8, with 4 analysts recommending between -$1.23 and -$2.49.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $11.67M. It ranges from a high estimate of $15M to a low estimate of $7.5M. As of the current estimate, Poseida Therapeutics Inc’s year-ago sales were $10.34M, an estimated increase of 12.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $11.67M, a decrease of -41.70% less than the figure of $12.80% in the same quarter last year. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 3 analysts have provided revenue estimates for PSTX’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $30M, resulting in an average revenue estimate of $46.67M. In the same quarter a year ago, actual revenue was $64.7M, down -27.90% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $28.33M in the next fiscal year. The high estimate is $45M and the low estimate is $10M. The average revenue growth estimate for next year is down -39.30% from the average revenue estimate for this year.
